Skip to content
Biodatica
Start free

Novartis Pharmaceuticals

Mobile, Alabama

OncologyFiled/ApprovedListed · NVS

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Filed/Approved trial registered: Roll-over Study to Allow Continued Access to Ribociclib

3w agoTrial registeredJun 23, 2026Source filing (opens the source filing in a new tab)

Momentum

87no change

Momentum 87 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Mar 20, 2026

    HR+/HER2- Advanced or Metastatic Breast Cancer · RECRUITING · sponsor: Novartis Pharmaceuticals · Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

    ClinicalTrials.gov · NCT07476170 (opens the source filing in a new tab)

  2. Trial

    Study registered

    May 30, 2024

    Metastatic HR+/HER2- Breast Cancer · COMPLETED · sponsor: Novartis Pharmaceuticals · A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

    ClinicalTrials.gov · NCT07086196 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Dec 27, 2022

    Neuroblastoma · TERMINATED · sponsor: Novartis Pharmaceuticals · Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

    ClinicalTrials.gov · NCT05429502 (opens the source filing in a new tab)

  4. Trial

    PHASE4 registered

    Jul 7, 2022

    Metastatic Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Novartis Pharmaceuticals · Roll-over Study to Allow Continued Access to Ribociclib

    ClinicalTrials.gov · NCT05161195 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Jun 11, 2019

    Breast Cancer · COMPLETED · sponsor: Novartis Pharmaceuticals · Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

    ClinicalTrials.gov · NCT03822468 (opens the source filing in a new tab)

  6. Trial

    PHASE3 registered

    May 5, 2011

    Neoplasms, Breast · COMPLETED · sponsor: Novartis Pharmaceuticals · A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

    ClinicalTrials.gov · NCT01160211 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources